VLX 101
Alternative Names: VLX-101Latest Information Update: 30 Apr 2025
At a glance
- Originator VALANX Biotech
- Class Amino acids; Cytokines; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Cytokine replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 30 Apr 2025 Preclinical trials in Autoimmune disorders in Austria (Parenteral) (Valanx Biotech pipeline, April 2025)
- 15 Dec 2022 VLX 101 is available for licensing as of 15 Dec 2022. https://www.valanx.bio/pipeline/
- 15 Dec 2022 Early research in Autoimmune disorders in Austria (Parenteral) before December 2022 (VALANX Biotech, December 2022)